Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study

This is a retrospective analysis on the safety and activity of compassionate Ipilimumab and Nivolumab (IPI-NIVO) administered to patients with metastatic Renal Cell Carcinoma (mRCC) with intermediate or poor International Metastatic RCC Database Consortium (IMDC) score as a first-line regimen. IPI w...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Umberto Basso, Federico Paolieri, Mimma Rizzo, Ugo De Giorgi, Sergio Bracarda, Lorenzo Antonuzzo, Francesco Atzori, Giacomo Cartenì, Giuseppe Procopio, Lucia Fratino, Manolo D’Arcangelo, Giuseppe Fornarini, Paolo Zucali, Antonio Cusmai, Matteo Santoni, Stefania Pipitone, Claudia Carella, Stefano Panni, Filippo Maria Deppieri, Vittorina Zagonel, Giampaolo Tortora
פורמט: Artigo
שפה:Inglês
יצא לאור: MDPI AG 2022-05-01
סדרה:Cancers
נושאים:
ipilimumab
nivolumab
metastatic Renal Cell Carcinoma
toxicity
progression
survival
גישה מקוונת:https://www.mdpi.com/2072-6694/14/9/2293
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים